Technical Analysis for IDXG - Interpace Diagnostics Group, Inc.

Grade Last Price % Change Price Change
grade F 0.7 -1.41% -0.01
IDXG closed up 1.46 percent on Tuesday, May 21, 2019, on 42 percent of normal volume.
4 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical IDXG trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction -1.41%
Narrow Range Bar Range Contraction -1.41%
BB Squeeze + Lower Band Touch Range Contraction -1.41%
Inside Day Range Contraction -1.41%
Lower Bollinger Band Touch Weakness -1.41%
Bollinger Band Squeeze Range Contraction 0.03%
BB Squeeze + Lower Band Touch Range Contraction 0.03%
Down 3 Days in a Row Weakness 0.03%
Lower Bollinger Band Touch Weakness 0.03%
Bollinger Band Squeeze Range Contraction -1.88%

Older signals for IDXG ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:

Profile
PDI, Inc. provides outsourced commercial services to pharmaceutical, biotechnology, diagnostics, and healthcare companies in the United States. It operates in two segments, Commercial Services and Interpace Diagnostics. The Commercial Services segment offers outsourced sales teams that target healthcare providers, providing a range of complementary sales support services designed to achieve its customers' strategic and financial product objectives. This segment offers a range of personal and non-personal promotional options for the commercialization of their products throughout the product lifecycles, from development through maturity. It also provides other promotional services, including clinical educator, teledetailing, and full product commercialization services. This segment's services include product distribution, personal and non-personal product detailing, full supply chain management, operations, sales, marketing, compliance, and regulatory/medical management. The Interpace Diagnostics segment focuses on developing and commercializing molecular diagnostic tests for physicians and patients with diagnostic options for detecting genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. This segment offers PancraGen, a diagnostic test designed for determining risk of malignancy in pancreatic cysts; and ThyGenX, a next-generation sequencing test designed to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules. It also has three diagnostic tests in late stage development that are designed to detect genetic alterations that are associated with gastrointestinal cancers; and one diagnostic test in late stage development that is designed to detect genetic alterations that are associated with endocrine cancers. PDI, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Biotechnology Cancer Healthcare Life Sciences Biology Supply Chain Management Healthcare Providers Diagnostic Tests Medical Genetics Qiagen
Is IDXG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 14 Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q1 2019 Results - Earnings Call Transcript
May 14 Edited Transcript of IDXG earnings conference call or presentation 13-May-19 8:30pm GMT
May 13 Interpace Diagnostics misses by $0.04, misses on revenue
May 13 Interpace Q1 revenue up 25%
May 13 Interpace Diagnostics Reports First Quarter 2019 Financial Results and Provides Business Update
May 9 Interpace Diagnostics BarreGEN® Data to be Presented at Digestive Disease Week
May 6 Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on Monday, May 13, 2019
May 1 Interpace Diagnostics Announces Publication of Important New Data on Thyroid Test Performance
Apr 29 Interpace Diagnostics Group, Inc.'s (NASDAQ:IDXG) Shift From Loss To Profit
Apr 25 Interpace Diagnostics Labs Receive College of American Pathology (CAP) Accreditation
See more IDXG news...
Indicators
Indicator Value
52 Week High 1.78
52 Week Low 0.67
Average Volume 315,218
200-Day Moving Average 1.0627
50-Day Moving Average 0.7818
20-Day Moving Average 0.7294
10-Day Moving Average 0.7212
Average True Range 0.0406
ADX 16.22
+DI 12.2011
-DI 18.4072
Chandelier Exit (Long, 3 ATRs ) 0.675
Chandelier Exit (Short, 3 ATRs ) 0.7918
Upper Bollinger Band 0.7652
Lower Bollinger Band 0.6936
Percent B (%b) 0.23
BandWidth 9.816287
MACD Line -0.0177
MACD Signal Line -0.0188
MACD Histogram 0.0011
Fundamentals Value
Market Cap 15.73 Million
Num Shares 22.2 Million
EPS -1.17
Price-to-Earnings (P/E) Ratio -0.61
Price-to-Sales 2.01
Price-to-Book 0.69
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.74
Resistance 3 (R3) 0.74 0.72 0.74
Resistance 2 (R2) 0.72 0.72 0.73 0.73
Resistance 1 (R1) 0.72 0.71 0.72 0.72 0.73
Pivot Point 0.70 0.70 0.71 0.71 0.70
Support 1 (S1) 0.70 0.70 0.70 0.70 0.69
Support 2 (S2) 0.68 0.69 0.69 0.69
Support 3 (S3) 0.68 0.68 0.69
Support 4 (S4) 0.68